View in EDS HTML Full Text PDF Full Text

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Saved in:
Bibliographic Details
Title: Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.
Authors: Capdevila J; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. jcapdevila@vhio.net.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. jcapdevila@vhio.net., Hernando J; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Molina-Cerillo J; Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain., Plana Serrahima M; Medical Oncology Department, Catalan Institute of Oncology (ICO), IDIBELL, ONCOBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Taberna Sanz M; Medical Oncology Department, Catalan Institute of Oncology (ICO), IDIBELL, ONCOBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Castelo B; Medical Oncology Department, University Hospital La Paz, Madrid, Spain., Álvarez-Escolá C; Endocrinology Department, University Hospital La Paz, Madrid, Spain., Carmona-Bayonas A; Medical Oncology Department, Hospital Universitario Morales Meseguer, Universidad de Murcia (UMU), IMIB, Murcia, Spain., Ballester Navarro I; Medical Oncology Department, Hospital Universitario Morales Meseguer, Universidad de Murcia (UMU), IMIB, Murcia, Spain., Iglesias L; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Bover M; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Garcia-Alvarez A; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Lavernia J; Medical Oncology Department, Hospital Fundación IVO (Instituto Valenciano de Oncología), Valencia, Spain., Yayá Tur R; Medical Oncology Department, Hospital Fundación IVO (Instituto Valenciano de Oncología), Valencia, Spain., Ruiz S; UGCI of Medical Oncology, Hospitales Regional y Universitario Virgen de la Victoria, IBIMA, UMA, Málaga, Spain., Baste N; Medical Oncology Department, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain., Lorenzo-Lorenzo I; Medical Oncology Service, Complejo Universitario Hospitalario de Vigo (CHUVI) Alvaro Cunqueiro, Vigo, Pontevedra, Spain., Sanchez-Hernandez A; Medical Oncology Service, Hospital Provincial de Castellón, Castellón de La Plana, Spain., Sanz-Garcia E; Medical Oncology Department, Centro Integral Oncológico 'Clara Campal', Hospital Universitario HM Sanchinarro, Madrid, Spain.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada., Marquina G; Medical Oncology Department, Hospital Clínico Universitario San Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain., Nuciforo P; Molecular Oncology Group, Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Elguero B; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Grande E; Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain., Alonso-Gordoa T; Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Source: Nature communications [Nat Commun] 2026 Apr 04; Vol. 17 (1). Date of Electronic Publication: 2026 Apr 04.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41935063
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Capdevila+J%22">Capdevila J</searchLink>; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. jcapdevila@vhio.net.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. jcapdevila@vhio.net.<br /><searchLink fieldCode="AU" term="%22Hernando+J%22">Hernando J</searchLink>; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Molina-Cerillo+J%22">Molina-Cerillo J</searchLink>; Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Plana+Serrahima+M%22">Plana Serrahima M</searchLink>; Medical Oncology Department, Catalan Institute of Oncology (ICO), IDIBELL, ONCOBELL, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Taberna+Sanz+M%22">Taberna Sanz M</searchLink>; Medical Oncology Department, Catalan Institute of Oncology (ICO), IDIBELL, ONCOBELL, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Castelo+B%22">Castelo B</searchLink>; Medical Oncology Department, University Hospital La Paz, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Álvarez-Escolá+C%22">Álvarez-Escolá C</searchLink>; Endocrinology Department, University Hospital La Paz, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Carmona-Bayonas+A%22">Carmona-Bayonas A</searchLink>; Medical Oncology Department, Hospital Universitario Morales Meseguer, Universidad de Murcia (UMU), IMIB, Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22Ballester+Navarro+I%22">Ballester Navarro I</searchLink>; Medical Oncology Department, Hospital Universitario Morales Meseguer, Universidad de Murcia (UMU), IMIB, Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22Iglesias+L%22">Iglesias L</searchLink>; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Bover+M%22">Bover M</searchLink>; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Garcia-Alvarez+A%22">Garcia-Alvarez A</searchLink>; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Lavernia+J%22">Lavernia J</searchLink>; Medical Oncology Department, Hospital Fundación IVO (Instituto Valenciano de Oncología), Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Yayá+Tur+R%22">Yayá Tur R</searchLink>; Medical Oncology Department, Hospital Fundación IVO (Instituto Valenciano de Oncología), Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Ruiz+S%22">Ruiz S</searchLink>; UGCI of Medical Oncology, Hospitales Regional y Universitario Virgen de la Victoria, IBIMA, UMA, Málaga, Spain.<br /><searchLink fieldCode="AU" term="%22Baste+N%22">Baste N</searchLink>; Medical Oncology Department, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Lorenzo-Lorenzo+I%22">Lorenzo-Lorenzo I</searchLink>; Medical Oncology Service, Complejo Universitario Hospitalario de Vigo (CHUVI) Alvaro Cunqueiro, Vigo, Pontevedra, Spain.<br /><searchLink fieldCode="AU" term="%22Sanchez-Hernandez+A%22">Sanchez-Hernandez A</searchLink>; Medical Oncology Service, Hospital Provincial de Castellón, Castellón de La Plana, Spain.<br /><searchLink fieldCode="AU" term="%22Sanz-Garcia+E%22">Sanz-Garcia E</searchLink>; Medical Oncology Department, Centro Integral Oncológico 'Clara Campal', Hospital Universitario HM Sanchinarro, Madrid, Spain.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Marquina+G%22">Marquina G</searchLink>; Medical Oncology Department, Hospital Clínico Universitario San Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Nuciforo+P%22">Nuciforo P</searchLink>; Molecular Oncology Group, Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Elguero+B%22">Elguero B</searchLink>; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Grande+E%22">Grande E</searchLink>; Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Alonso-Gordoa+T%22">Alonso-Gordoa T</searchLink>; Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2026 Apr 04; Vol. 17 (1). <i>Date of Electronic Publication: </i>2026 Apr 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41935063
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-026-71155-y
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Capdevila J
      – PersonEntity:
          Name:
            NameFull: Hernando J
      – PersonEntity:
          Name:
            NameFull: Molina-Cerillo J
      – PersonEntity:
          Name:
            NameFull: Plana Serrahima M
      – PersonEntity:
          Name:
            NameFull: Taberna Sanz M
      – PersonEntity:
          Name:
            NameFull: Castelo B
      – PersonEntity:
          Name:
            NameFull: Álvarez-Escolá C
      – PersonEntity:
          Name:
            NameFull: Carmona-Bayonas A
      – PersonEntity:
          Name:
            NameFull: Ballester Navarro I
      – PersonEntity:
          Name:
            NameFull: Iglesias L
      – PersonEntity:
          Name:
            NameFull: Bover M
      – PersonEntity:
          Name:
            NameFull: Garcia-Alvarez A
      – PersonEntity:
          Name:
            NameFull: Lavernia J
      – PersonEntity:
          Name:
            NameFull: Yayá Tur R
      – PersonEntity:
          Name:
            NameFull: Ruiz S
      – PersonEntity:
          Name:
            NameFull: Baste N
      – PersonEntity:
          Name:
            NameFull: Lorenzo-Lorenzo I
      – PersonEntity:
          Name:
            NameFull: Sanchez-Hernandez A
      – PersonEntity:
          Name:
            NameFull: Sanz-Garcia E
      – PersonEntity:
          Name:
            NameFull: Marquina G
      – PersonEntity:
          Name:
            NameFull: Nuciforo P
      – PersonEntity:
          Name:
            NameFull: Elguero B
      – PersonEntity:
          Name:
            NameFull: Grande E
      – PersonEntity:
          Name:
            NameFull: Alonso-Gordoa T
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 04
              Text: 2026 Apr 04
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1